Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Q1 2021 Correction?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Jan 02, 2021 2:09pm
161 Views
Post# 32209694

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Q1 2021 Correction?

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Q1 2021 Correction?
Danorrn wrote:
AntibeTribe wrote:
Mole101 wrote: Covid it's known to affect the brain too.. you should get it check and get some help T .. ' delusional' appears to be your ailment ... you're going on ignore ! DumbAss


Bro, it's 'cause we are all just NOT WOKE enough to see what Bill Gates, Hillary Clinton and the untold millions in the BLM movement have been doing with this plandemic!!! T has secret knowledge the rest of us aren't privy too. Secret 5G, Flat Earth, nazi knowledge.


Don't forget the chinese and the "great reset button" lmao. F'ing covidiots are everywhere. Come to my hospital and watch our ICU for just a few days. Watch the inpatient become outpatients but not in a good way. What an A$$


Thanks for sharing Danorrn.
Good to hear from people like you who see it happening in communities.
Too many conspiracy theories and
personal opinions trying to get to us gift wrapped as facts.

hahaha
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities